- Moderna announced on Monday that its early trial for its coronavirus vaccine produced antibodies in all patients.
- Shares of the company surged 39% on Monday.
- The company is aiming to have the vaccine ready for emergency use in the fall.Watch Moderna trade live on Markets Insider.
Moderna is soaring after an early trial of its coronavirus vaccine produced positive results, the company announced Monday.
Shares of the pharmaceutical company surged as much as 39% in premarket trading Monday in New York after it announced that all 45 volunteers in a trial for its coronavirus vaccine produced antibodies that may help protect them against the disease.
The phase 1 trial was conducted by the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health.
FAUCI GOT AN EARLY START – JANUARY!
In JANUARY 2020, Moderna announced development of a vaccine to inhibit COVID-19 in competition with Gilead, Vaxart, Inovio, Novamax.
In March 2020, the Phase I human study of the vaccine candidate began in partnership with the US NIAID (that’s Fauci’s outfit).” (Wikipedia)
Moderna plans to have the drug ready for potential emergency use in the fall — a timeline that’s never been seen for vaccine development before. Following the phase 1 trial, the company hopes to soon start a mid-stage study of the vaccine and move to a late-stage trial in July.
Moderna is one of a handful of pharmaceutical companies that have skyrocketed amid the coronavirus crisis as they race to develop drugs to prevent or treat the disease. The pharmaceutical company has gained 241% year-to-date through Friday’s close.